Clinical Evidence: What the Data Actually Shows
Mounjaro Versus Wegovy: Understanding the Clinical Trial Evidence
When evaluating Mounjaro versus Wegovy, the clinical evidence provides crucial insights into how these treatments perform in real-world studies. The landmark STEP trials for Wegovy, published by Wilding et al. in the New England Journal of Medicine (2021), demonstrate significant weight management outcomes when combined with lifestyle interventions. In STEP 1, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo.
The Mounjaro versus Wegovy comparison becomes more nuanced when examining their different mechanisms of action. Wegovy (semaglutide) works as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) functions as a dual GIP and GLP-1 receptor agonist. Both medications require clinical assessment and ongoing prescriber support, which EverydayMeds provides through our GPhC-registered pharmacy (#9012878). The STEP 5 extension study showed sustained weight management with approximately clinically studied weight loss maintained at 2 years, highlighting the importance of long-term treatment commitment.
Wegovy Pricing and Value: Making Treatment Accessible
Understanding the cost implications when comparing Mounjaro versus Wegovy helps patients make informed decisions about their weight management journey. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the 2.4mg maintenance dose (£209.99). New customers can apply discount code FIRST40 at checkout, whilst returning patients use code DOSE25 to reach these final prices.
Our bundle options provide treatment continuity without multiple ordering requirements. The Intro Trio bundle (0.25mg, 0.5mg and 1mg) costs £299.99, covering the first 12 weeks of dose escalation. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99. These bundles ensure uninterrupted treatment progression, which is essential since dose escalation cannot be skipped when using this prescription-only medicine.
STEP Clinical Trial Results: What Patients Achieved
The evidence base for Wegovy comes from the comprehensive STEP clinical trial programme, providing robust data for the Mounjaro versus Wegovy discussion. STEP 3 demonstrated approximately clinically studied weight loss when Wegovy was combined with intensive behavioural therapy, whilst STEP 2 showed 9.6% weight reduction in patients with type 2 diabetes. These results represent average outcomes in controlled clinical settings alongside dietary and exercise interventions.
The SELECT cardiovascular outcomes trial adds another dimension to the clinical evidence, showing a 20% reduction in major cardiovascular events with Wegovy treatment. This data, published in peer-reviewed journals, helps inform prescriber decisions when patients are considering their options. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which treatment aligns with your individual circumstances.
How Wegovy Works: The GLP-1 Mechanism
Understanding the mechanism helps clarify the Mounjaro versus Wegovy comparison from a scientific perspective. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone involved in appetite regulation and glucose homeostasis. This prescription-only medicine works by binding to GLP-1 receptors in the brain's appetite centres, promoting feelings of satiety after smaller meals and potentially reducing food cravings. The medication also slows gastric emptying, which contributes to prolonged fullness and helps patients adhere to reduced-calorie eating patterns. Clinical studies suggest that patients may experience decreased appetite within the first few weeks of treatment, though individual responses vary considerably.
EverydayMeds Ordering Process: From Assessment to Delivery
The process for obtaining either medication in the Mounjaro versus Wegovy comparison begins with our 3-minute online clinical assessment, designed to gather essential medical history and current health information. Once submitted, our registered prescribers review each case individually, with standard review completed within 3 working days or express 24-hour service available for urgent requirements. Following prescriber approval, medications are dispatched the same day through our temperature-controlled cold-chain delivery system, ensuring medication integrity throughout transit. All Wegovy pens arrive with comprehensive injection guidance and dose escalation schedules, supporting patients through their treatment journey. Our clinical team remains available for ongoing support and guidance throughout your weight management programme.
Storage and Practical Considerations: Wegovy's Travel Advantage
Practical aspects often influence patient choice in the Mounjaro versus Wegovy decision, particularly regarding storage requirements and lifestyle compatibility. Wegovy pens must be stored in the refrigerator at 2-8°C before first use, but can remain at room temperature below 30°C for up to 6 weeks once removed from refrigeration—significantly longer than Mounjaro's 21-day room temperature limit. The FlexTouch pen system provides precise dosing with audible and tactile feedback, making self-injection straightforward even for injection-naïve patients. Dose escalation follows a structured 4-week schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg maintenance from week 17 onwards. This gradual increase helps minimise potential gastrointestinal side effects whilst allowing the body to adapt to the medication's effects.
UK-Specific Clinical Evidence and NICE Recommendations
The UK medical landscape provides specific guidance for the Mounjaro versus Wegovy comparison through NICE technology appraisal TA875, which recommends Wegovy for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. This recommendation specifically requires specialist weight management support, which aligns with EverydayMeds' clinical assessment and ongoing prescriber monitoring approach. The MHRA has licensed Wegovy for weight management when combined with lifestyle interventions, recognising the clinical evidence from the STEP programme.
UK-specific considerations include the medication's Black Triangle status (▼), indicating additional monitoring by the MHRA as a relatively new therapeutic option. Weight regain data from STEP 1 extension studies shows patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that weight management requires long-term commitment rather than short-term intervention. This evidence helps patients understand realistic expectations and the importance of ongoing treatment adherence.
Making Your Decision: Clinical Support and Next Steps
The Mounjaro versus Wegovy choice ultimately depends on individual medical circumstances, lifestyle factors, and prescriber guidance based on current clinical evidence. Both treatments are prescription-only medicines requiring thorough medical assessment and ongoing monitoring throughout treatment. EverydayMeds provides access to both options through our comprehensive clinical assessment process, ensuring patients receive appropriate treatment based on their specific circumstances. Our GPhC-registered pharmacy (#9012878) maintains strict quality standards for medication sourcing and cold-chain distribution, guaranteeing genuine Novo Nordisk Wegovy pens reach patients in optimal condition. Begin your clinical assessment today using discount code FIRST40 for new customers or DOSE25 for returning patients, and take the first step towards evidence-based weight management support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
